Germline mutations in two major susceptibility genes, BRCA1 and BRCA2, account for nearly 20% of familial breast cancers. A majority of the remaining genetic factors involved in heritable breast cancer susceptibility are, however, unknown. Recently, a new BRCA1-interacting protein, receptor associated protein 80 (RAP80), was identified. RAP80 plays an important role in BRCA1-mediated DNA damage responses (DDRs) by recruiting BRCA1 to DNA double-strand breaks (DSBs). A comprehensive screening of DNA from affected index cases of 112 BRCA1/BRCA2 mutation-negative Finnish breast cancer families revealed altogether 10 alterations in RAP80, one of which, c.241-243delGAA, resulted in a single glutamic acid deletion at residue 81 in a highly conserved region of ubiquitin interaction motif 1. The resultant delE81 protein product displayed significantly reduced ubiquitin binding and DSB localization. Expression of the RAP80 delE81 allele impaired both BRCA1 and ABRA1 DSB recruitment, thus compromising BRCA1-mediated DDR signaling. Compared with wildtype RAP80, expression of the delE81 allele was associated with a significant increase in cytogenetically detectable chromosomal aberrations, particularly chromatid breaks. Although evidently quite rare, these results suggest that critical constitutional mutations in RAP80 abrogate DDR function and may be involved in genetic predisposition to cancer.
Introduction
Approximately 5-10% of all breast cancers stem from hereditary predisposition to the disease. Mutations in the two main susceptibility genes BRCA1 and BRCA2 (also called FANCD1), together with mutations in a number of other high-penetrance genes such as TP53 and PTEN, account for 20% of familial breast cancer cases. For the remaining 80%, the genetic factors are largely unknown and are likely to involve mutations in moderate-and low-penetrance susceptibility genes, plausibly acting together with certain environmental or other hereditary factors (Rahman and Stratton, 1998; Schwab et al., 2002; Wooster and Weber, 2003; Stratton and Rahman, 2008) . However, the involvement of rare constitutional mutations in additional unknown highpenetrance gene(s) cannot currently be ruled out.
BRCA1 and BRCA2 are linked to various processes involved in the DNA damage response (DDR), including both repair of DNA double-strand breaks (DSBs) and checkpoint control. Furthermore, BRCA1 and BRCA2 reside in part as members of a biochemically active multiprotein complex and colocalize at sites of DNA damage. This suggests that functions carried out by BRCA1/BRCA2-containing complexes in the DDR are necessary for both genome integrity and the suppression of breast and ovarian epithelial malignancies Greenberg et al., 2006) . Consequently, the genes encoding proteins interacting with BRCA1 or BRCA2 could represent important candidates for harboring new cancer susceptibility alleles.
Consistent with this notion, breast cancer susceptibility alleles in BRIP1 (also called FANCJ or BACH1) and PALB2 (alias FANCN) have been detected because of earlier identification of each of these proteins as important mediators of BRCA1 and BRCA2 DNA repair activities. Moreover, BRCA1 is extensively phosphorylated by the checkpoint kinases and breast cancer suppressors ATM and CHK2, and such phosphorylation events are necessary for DNA damage inducible formation of supercomplexes with members of the MRN complex (composed of MRE11, RAD50 and NBS1) and TOPBP1 (Topoisomerase II a binding protein 1) (Greenberg et al., 2006) . Mutations in the genes encoding these BRCA1-interacting proteins have also been associated with breast cancer susceptibility Karppinen et al., 2006; Stratton and Rahman, 2008) .
Recently, a new BRCA1-associated complex has been identified, consisting of a set of proteins that interacts with the BRCA1 C-terminal (BRCT) repeat domains. RAP80 (receptor associated protein 80 alias UIMC1 ubiquitin-interacting motif containing 1) was identified as a BRCA1-BRCT-binding protein on the basis of its co-immunoprecipitation with BRCA1 during purification of the BRCA1-BARD1 complexes (Kim et al., 2007a; Sobhian et al., 2007; Yan et al., 2007) . The BRCA1-RAP80 association is mediated in a phosphorylation-dependent manner by ABRA1 (Abraxas alias CCDC98), in which the BRCT repeats of BRCA1 form a direct biochemical interaction with phosphorylated ABRA1. This interaction bridges BRCA1 association with the RAP80 complex, which also includes BRCC36, a deubiquitinating enzyme with specificity for lysine 63-linked ubiquitin chains (K63-Ub) (Sobhian et al., 2007) . RAP80 is required for the accumulation of BRCA1 and the other members of this complex to ionizing radiation-induced foci (IRIF). RAP80 migrates to IRIF and, through its tandem ubiquitin interaction motif (UIM) domains, targets BRCA1, ABRA1 and BRCC36 to K63-Ub at DSBs (Kim et al., 2007b; Liu et al., 2007; Sobhian et al., 2007; Wang and Elledge, 2007) . The ubiquitin structures recognized by RAP80 are formed in response to a series of signaling events emanating from MDC1 (mediator of DNA damage checkpoint protein 1) binding to phosphorylated histone H2AX (gH2AX) at chromatin regions adjacent to DSBs (Kim et al., 2007a; Sobhian et al., 2007) . This phosphorylation-dependent interaction targets the RNF8 E3 ligase in association with the K63-Ub-specific E2 enzyme UBC13 (alias UBE2N) to DSB sites to synthesize K63-Ub on histones H2A and gH2AX, providing a strong DSB targeting signal for RAP80-containing complexes (Huen et al., 2007; Kolas et al., 2007; Mailand et al., 2007; Wang and Elledge, 2007; Zhao et al., 2007) . As a consequence, RAP80 plays a critical role in BRCA1-mediated DDR signaling and harmful changes in this gene might lead to a disruption of genomic integrity, thus facilitating cancer development.
To explore the possibility that constitutional mutations in RAP80 are associated with an increased risk of developing cancer, blood sample DNA of affected index cases from 112 Finnish BRCA1/BRCA2 mutationnegative breast cancer families were comprehensively screened for possible mutations. One of the alterations observed, 243delGAA (delE81), mapped to a highly conserved region in the functionally important UIM1 domain and this change abrogated ubiquitin binding and DDR function for RAP80 and other members of the RAP80-BRCA1 protein complex. These results suggest that the RAP80 delE81 defect is biologically relevant and might be connected to hereditary predisposition to cancer.
Results

RAP80 mutation screening
The screening for RAP80 mutations in affected index cases from 112 BRCA1/BRCA2 mutation-negative breast cancer families revealed altogether 10 germline alterations (Table 1) . Eight of the detected changes were in exon regions and two were in intron regions. One of the exonic alterations was novel and seven had been reported earlier (Akbari et al., 2009; Osorio et al., 2009) . All detected variants were checked for potential splicing defects using NNsplice software (http://www.fruitfly. org/seq_tools/splice.html); however, nothing abnormal was detected. We used ESEfinder 2.0 software (http:// rulai.cshl.edu/tools/ESE/) to identify exonic alterations that fall within predicted exonic splicing enhancer sequences that could possibly affect exonic splicing enhancer functions (summarized in Table 1 ).
Of the genetic alterations detected, one was located in a functional domain, suggesting potential deleterious effects on RAP80 functions in the DDR (Figure 1a ). RAP80 germline mutation impairs DNA damage response J Nikkilä et al
The location of this observed amino acid change is shown in Figure 1a . The alteration was a novel exonic change, c.241-243delGAA (delE81), leading to an inframe deletion of one of the three consecutive glutamic acid residues located at the functionally significant UIM1 domain ( Figure 1a and Supplementary Figure  1 ). This three amino acid stretch of glutamic acid residues is evolutionarily conserved between all the vertebrate RAP80 species (Figure 1b) . Furthermore, the RAP80 UIM1 domain is required for RAP80-BRCA1 complex migration to ubiquitin polymers at DSBs (Kim et al., 2007a; Sobhian et al., 2007; Yan et al., 2007) . The delE81 variant was identified in a patient diagnosed with breast cancer at the age of 60. The patient's maternal aunt had also been diagnosed with breast cancer (at unknown age). Information regarding other family members and their health status was incomplete. Thus, segregation analysis of the RAP80 delE81 allele with regard to cancer incidence was not possible owing to a lack of DNA samples from relatives. The observed frequency for the delE81 variant was 0.9% (1/112) in the familial cases compared with 0.3% (1/325) in the controls (P ¼ 0.45; OR ¼ 2.92; CI ¼ 0.18-47.1). The mutational status in 503 unselected breast cancer cases was also assessed and revealed one delE81 carrier (0.2%, 1/503), who was diagnosed with bilateral breast cancer at a relatively young age (39 and 41 years). The family history of cancer for this patient is unknown. To test for possible loss of the wild-type (WT) allele in the two mutation-positive patients, loss of heterozygosity (LOH) analysis was performed on available tumor specimens. We did not detect loss of the normal RAP80 allele in either case (data not shown).
DelE81 mutation disrupts RAP80 ubiquitin binding and double-strand break localization
Mutation of either of the RAP80 tandem UIM domains impairs ubiquitin binding (Kim et al., 2007a; Sobhian et al., 2007) and DSB localization (Kim et al., 2007a; Sobhian et al., 2007; Yan et al., 2007) . RAP80 UIM1 exhibits high sequence similarity to several UIM domains from other proteins, including the UIM domain from Vps27, a ubiquitin-binding protein identified from yeast. The structure of Vps27 bound to ubiquitin reveals a critical hydrogen bonding interaction between the carboxy side chain of E259 of Vps27 and the main chain atoms of L71 and R72 in the C-terminal region of ubiquitin (Swanson et al., 2003) . This is illustrated in the ribbon diagram that was generated by coordinate data from the NMR structure of Vps27 and ubiquitin ( Figure 1c ). Homology modeling of RAP80 on the basis of the Vps27-ubiquitin structure RAP80 germline mutation impairs DNA damage response J Nikkilä et al reveals that E81 of RAP80 aligns with the critical E259 of Vps27. Indeed, in an alignment of UIM domains from the Pfam database (http://pfam.sanger.ac.uk/ accession number PF02809), this position is either glutamic acid or aspartate in 94% of the 756 aligned family members/sequences. On the basis of the Vps27-ubiquitin structure, it is predicted that RAP80 delE81 may have a reduced binding affinity for ubiquitin.
To determine if RAP80 delE81 is deficient in ubiquitin recognition, we incubated a GST-fusion protein encompassing amino acids 1-132 of either WT RAP80 or RAP80 delE81 with a mixture of K63-Ub polymers containing from 2 to 7 ubiquitin molecules that were epitope tagged with six histidine residues (His-K63-Ub). A GST-BRCA1 fragment containing residues 1005-1313 of BRCA1 (GST-B1F5) was also tested for ubiquitin binding as a negative control. After a 2 h incubation period, His-K63-Ub was purified over Ni 2 þ -agarose beads and eluted in imidazole containing buffer. The immunoblot revealed a readily detectable association between GST-RAP80 WT and K63-Ub, but both GST-RAP80 delE81 and GST-B1F5 failed to co-precipitate with equivalent amounts of K63-Ub (Figure 2a ). Reciprocal binding of RAP80 and K63-Ub was examined using RAP80 fragments containing six amino-terminal histidine residues (His 6 -SUMOFigure 2 RAP80 delE81 shows reduced ubiquitin binding and localization to damage sites. (a) A GST-RAP80 fusion protein encompassing amino acids (aa) 1-132 of RAP80 was incubated with His-K63-Ub chains containing 2-7 ubiquitin monomers and reactions were precipitated by affinity chromatography on Ni 2 þ -agarose beads. B1F5, a BRCA1 fragment that does not interact with ubiquitin, is shown as a negative control. Immunoblot was performed as indicated. (b) His-RAP80 fragments were incubated with K63-Hexa-Ub and reactions were purified by affinity chromatography on Ni 2 þ -agarose beads. Immunoblot was performed as indicated. (c) U2OS cells transfected with GFP-RAP80 or GFP-RAP80 delE81 were treated with ionizing radiation (10 Gy) and fixed after 3 h. RAP80, delE81 and gH2AX localization to DNA double-strand breaks (DSBs) was examined using GFP fluorescence and anti-gH2AX immunostaining. (d) Recruitment of HA epitope tagged WT RAP80 and RAP80 delE81 to laser-induced DSB stripes. Cells were fixed 30 min after stripe induction and immunofluorescence was performed with anti-HA and anti-gH2AX antibodies. RAP80 1-132 WT vs His 6 -SUMO-RAP80 delE81 1-132 ) and untagged K63-Ub 2-7 . WT or mutant RAP80 species were precipitated with Ni 2 þ -agarose beads and eluted with imidazole as above. Purified material was examined by immunoblot with antibodies against RAP80 and ubiquitin. WT RAP80 again showed association with K63-Ub, preferentially associating with K63-Ub polymers of four ubiquitin units, as reported earlier (Sobhian et al., 2007) . RAP80 delE81 showed greatly reduced, albeit detectable, K63-Ub binding (Figure 2b) .
A strong correlation between RAP80 ubiquitin binding and DSB localization has been reported (Kim et al., 2007a; Sobhian et al., 2007; Yan et al., 2007) . We thus examined RAP80 localization to IRIF 3 h after 10 Gy of IR. GFP-tagged RAP80 colocalized with gH2AX in approximately 80% of cells examined, whereas RAP80 delE81 showed discernable foci in o10% of the studied cells (N>200) (Figure 2c ). These results strongly indicate that RAP80 delE81 has impaired, albeit not completely absent, DSB localization. To determine if RAP80 delE81 is capable of any DSB retention, a linear array of DSBs was generated in a defined subnuclear volume using a 337 nm wavelength UV laser as described earlier (Rogakou et al., 1999; Sobhian et al., 2007) . WT RAP80 strongly localized to laser induced DSBs. RAP80 delE81 showed weaker, but still present, DSB localization, suggesting that the delE81 variant has impaired, but not completely absent, DSB recognition function (Figure 2d ). RAP80 delE81 expression abrogates DSB localization for the RAP80-ABRA1-BRCA1 complex To investigate the possibility that RAP80 delE81 is dominantly interfering with BRCA1 recruitment to foci, endogenous BRCA1 was immunoprecipitated from U2OS cell lines expressing ectopic Flag-HA tagged RAP80 WT and RAP80 delE81 species. BRCA1 displayed similar association with both WT and RAP80 delE81, as well as with other members of this complex, ABRA1 and BRCC36 (Figure 3a) . To determine if each RAP80 species can associate with other known binding partners, immunoprecipitation was performed on ectopically expressed Flag-HAtagged RAP80 WT and RAP80 delE81 from U2OS cells using anti-Flag antibody-conjugated beads and eluted with Flag peptide. WT RAP80 and RAP80 delE81 displayed equivalent association with ABRA1 and BRCC36 (Figure 3b ). These results suggest that RAP80 delE81 could function as a dominant-negative allele by associating with known binding partners, yet largely failing to recognize DNA DSBs. It is noted that BRCA1 IRIF were reduced in intensity in cells expressing RAP80 delE81 compared with BRCA1 foci in cells expressing WT RAP80, suggesting a dominant interfering effect of RAP80 delE81 on BRCA1 DSB localization (Figure 3c ). In line with this hypothesis, ABRA1 IRIF were also reduced significantly in RAP80 delE81-expressing cells compared to cells expressing WT RAP80 (Figure 3d ), revealing that RAP80 delE81 expression impairs DSB recognition for members of its associated complex. RAP80 delE81-expressing cells exhibit genomic instability As BRCA1 recruitment in delE81-expressing cells is compromised, we hypothesized that these cells may have deficiencies in DSB repair, leading to genomic instability and the accumulation of chromosomal abnormalities. To investigate this possibility, we examined metaphase spreads from cells expressing WT RAP80 or RAP80 delE81. Cells expressing the delE81 variant exhibited a significant increase in chromosomal aberrations, of which the majority were sister chromatid breaks (Figures 4a and b) . These cytogenetic abnormalities are characteristic of cells with DSB repair deficiencies (Patel et al., 1998; Xu et al., 1999; Celeste et al., 2002; Lou et al., 2006) .
Discussion
Germline mutations disrupting the function of the BRCA1 or BRCA2 genes cause predisposition to cancer. For example, mutations in BRCA1 confer up to an 85% lifetime risk of developing breast cancers and up to a 50% lifetime risk of ovarian epithelial cancers (King et al., 2003) . However, the genetic susceptibility to breast cancer cannot be fully attributed to mutations in BRCA1 or BRCA2 (Moynahan et al., 1999; Scully et al., 1999; Xu et al., 2001) . Therefore, germline mutations that result in abnormal expression or function of BRCA1-interacting proteins might have an effect on cancer development (Seal et al., 2006) . Accordingly, in BRCA1, the BRCT domain is the most common site of missense mutations and such breast cancer causing alterations invariably disrupt BRCT domain proteinprotein interactions and DSB recognition. Known BRCT-interacting partners, BRIP1 and TOPBP1, fail to associate with clinical BRCT mutants (Cantor et al., 2001; Greenberg et al., 2006) and germline alterations in these two genes have been associated with breast cancer susceptibility Seal et al., 2006) . Thus, additional BRCT-interacting proteins, like RAP80, that contribute to BRCA1 function in the DDR represent an important source of candidate breast cancer susceptibility genes (Wong et al., 1998; Yu et al., 1998; Cantor et al., 2001; Kim et al., 2007a; Sobhian et al., 2007; .
To explore whether variations in RAP80 are associated with hereditary predisposition to breast cancer, we performed a comprehensive screening for germline alterations in the RAP80 gene. Of the observed alterations, the delE81 variant seemed to have an obvious biological significance because of its location in the UIM1 domain. As delE81 is located in a functionally significant domain of RAP80, we investigated the effect this variant has on RAP80 function. We established that the RAP80 delE81 variant has a reduced capacity to bind K63-linked ubiquitin compared with WT RAP80 and subsequently delE81 has reduced localization to IRIF and also to laser-induced DSBs, suggesting that the diminished ubiquitin binding leads to a decrease in RAP80 delE81 retention at sites of damage. These deficiencies in DSB targeting were associated with a significant increase in sister chromatid breaks in RAP80 delE81-expressing cells.
RAP80 delE81 maintains WT levels of interaction with known binding partners BRCA1, ABRA1 and BRCC36. Interestingly, we noted that RAP80 delE81-expressing cells exhibit reduced BRCA1 and ABRA1 foci in response to DNA damage. This phenomenon suggests that the delE81 variant may be acting as a dominant-negative, still interacting with binding partners, yet largely failing to recruit these proteins to sites of damage. These results may explain why LOH was not evident for the WT RAP80 allele in tumors from delE81 patients. Similarly, tumors of individuals heterozygous for germline mutations in either PALB2 or BRIP1 also failed to show loss of the corresponding WT allele (Seal et al., 2006; Erkko et al., 2007) . Furthermore, if RAP80 (Patel et al., 1998; Xu et al., 1999) . In addition, cells deficient in gH2AX and MDC1, mediators of RAP80 recruitment, also exhibit increases in chromatid breaks (Celeste et al., 2002; Lou et al., 2006) . Accordingly, cells expressing the delE81 variant exhibited a significant increase in sister chromatid breaks, indicating that DSBs are not repaired with the same fidelity as those expressing WT RAP80, strongly supporting the importance of DSB ubiquitin recognition by RAP80-BRCA1 complexes in genome integrity maintenance. The RAP80 delE81 allele may thus represents a new alternative mechanism of disrupting BRCA1 DSB repair function by maintaining BRCA1 protein associations, yet abrogating BRCA1 localization to DNA damage sites. Although others have recently investigated the occurrence of RAP80 mutations in moderate-to high-risk breast cancer families (Novak et al., 2008; Akbari et al., 2009; Osorio et al., 2009) , the current study is the first to identify a loss of function allele in this gene. The heterozygous delE81 alteration was identified from two patients, one of which had a moderate familial background of cancer and the other that had been diagnosed with bilateral breast cancer at ages 39 and 41. Unfortunately, it was not possible to clarify whether there were other affected individuals among close relatives for the bilateral case. The delE81 allele was also identified in one 49-year old control individual. However, because of the relatively young age of this person compared with the two affected mutation-positive individuals, she may not yet be old enough to express the disease phenotype. Indeed, the majority of germline BRCA1 and BRCA2 mutation carriers display cancer phenotypes only after the age of 50 (King et al., 2003) .
Although the prevalence of the observed RAP80 delE81 mutation was not statistically significant in our case cohort, this is likely because of a combination of extremely low allele frequency and incomplete disease penetrance. Currently, it seems that all individuals displaying the observed and relatively rare RAP80 delE81 germline mutation originate from the same limited geographical region in northern Finland. If the affected site represents a mutational hotspot, we would expect it to occur in other geographical settings. Studies in additional populations will be needed to understand the prevalence of this allele in other locations. Furthermore, it would be interesting to learn whether any other members of this biologically essential BRCA1-containing protein complex, such as BRCC36 or ABRA1, will reveal genetic alterations associated with hereditary predisposition to cancer.
Although the RAP80 protein has two UIM domains, it is intriguing that loss of a single amino acid from UIM1 is significantly detrimental to ubiquitin binding and DSB targeting. The importance of the RAP80 UIM domains has been established through extensive mutational studies, in which UIM1 or UIM2 point mutations showed reduced RAP80 recruitment to IRIF (Kim et al., 2007a; Sobhian et al., 2007; Yan et al., 2007) . As mutations in either UIM1 or UIM2 abrogate RAP80 IRIF formation, it seems that there may be cooperative binding of ubiquitin to the tandem UIMs. This is also supported by the fact that RAP80 most efficiently binds tetramers of K63-Ub (Figure 2b , Sobhian et al., 2007) . These data imply that RAP80 needs multiple ubiquitin binding sites for efficient recognition of DNA damage sites. The tandem UIMs of RAP80 may provide the ability to bind specific ubiquitin structures that are present at DSBs. The relative contribution of each UIM domain within RAP80 is not currently understood. Further studies into the structural association between ubiquitin polymers and the tandem RAP80 UIMs will lend insight into how the E81 residue helps facilitate ubiquitin binding and how each UIM domain contributes to RAP80 specificity for K63-Ub chains.
To our knowledge, this is the first report of a UIM mutation in association with cancer predisposition. The importance of ubiquitin signaling in the DDR and tumor suppression is well established (Huang and D'Andrea, 2006; Harper and Elledge, 2007; Greenberg, 2008; Yan and Jetten, 2008) . BRCA1 provides a prominent example of this intimate relationship between ubiquitin signaling, genome integrity and tumor suppression. BRCA1 has E3 ligase activity through its RING domain (Hashizume et al., 2001; Ruffner et al., 2001; Baer and Ludwig, 2002) and recognizes K63-Ub at DSBs in association with RAP80 (Kim et al., 2007a; Sobhian et al., 2007; Yan et al., 2007) . Although BRCA1 E3 targets have not been well characterized, cancer predisposing mutations in the RING domain have been identified indicating the importance of ubiquitin ligase activity in the tumor suppressive functions of BRCA1 (Ruffner et al., 2001) . These data, along with our findings on the delE81 variant, underscore the importance of both ubiquitin signaling and recognition in DNA damage repair and maintenance of genomic stability.
Materials and methods
Subjects
Affected index cases of 112 breast cancer families from northern Finland were screened for germline mutations in the coding regions and exon-intron boundaries of the RAP80 gene. Of the studied families, 65 were high-risk families, defined as follows: (1) three or more cases of breast and/or ovarian cancer in firstor second-degree relatives or (2) two cases of breast cancer in first-or second-degree relatives, of which at least one with early disease onset (p35 years), bilateral disease or multiple primary tumors. Most of the high-risk families displayed three or more cancer cases. The remaining 47 families with moderate disease susceptibility displayed two cases of breast cancer in first-or second-degree relatives. All of the studied families had earlier been screened for germline mutations in the BRCA1, BRCA2, TP53, CHK2, ATM, RAD50 and PALB2 genes and were found negative for BRCA1/2 mutations (Huusko et al., 1998 , 2007) . In this study, 325 DNA samples from anonymous cancer-free female individuals were used as controls. All control samples derived from Finnish Red-Cross blood donors originated from the same geographical region as the studied cancer cases. The age of the blood donors was X40 years. In addition, the presence of the RAP80 delE81 variant was tested in 503 incident female breast cancer cases not selected for or against a family history of cancer. All patients gave their informed consent to participate in the study. This study was approved by the Ethical Board of the Northern Ostrobothnia Health Care District and the Finnish Ministry of Social Affairs and Health.
DNA extraction and mutation analysis Genomic DNA was extracted from blood lymphocytes using the standard phenol-chloroform method or the Puregene D-50K purification kit (Gentra, Minneapolis, MN, USA). Mutation screening of the RAP80 gene (GenBank ID: 51720, protein; NM_016290.3) was carried out by conformation sensitive gel electrophoresis (Supplementary Figure 1) , which has proven to be a simple and accurate method for detecting sequence variants (Ko¨rkko¨et al., 1998) . All positive results were confirmed by reamplification of the original sample and direct sequencing with the Li-Cor IR 2 4200-S DNA Analysis system (Li-Cor, Inc., Lincoln, NE, USA) using the Sequi Therm EXEL II DNA Sequencing Kit-LC (Epicentre Technologies, Madison, WI, USA). All oligonucleotides used (see Supplementary Table S1 ) were designed by Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), using sequence information obtained from public databases.
Allelic imbalance analysis
Loss of heterozygosity analysis was carried out to assess whether the tumors of patients displaying the RAP80 delE81 germline mutation had lost the WT allele. DNA was extracted from paraffin embedded tumors and normal tissue-pairs using standard procedures (Isola et al., 1994) . For LOH analysis a segment flanking the observed three base pair deletion in exon 4 was amplified using an IRD800-labeled forward primer and the obtained PCR products were analysed with the Li-Cor Analysis system. Gene Profiler 4.05 software (Scanalytics, Inc., Fairfax, VA, USA) was used to quantify allele intensity ratios, and the allelic imbalance (AI) measuring the LOH was calculated from the formula AI ¼ (T2 Â N1)/(T1 Â N2), where T1/2 stands for tumor and N1/2 the equivalent normal allele. A value >1.67 or o0.60 was considered to indicate AI, meaning that the intensity of one of the alleles had decreased more than 40% (Tuhkanen et al., 2004) . Results from the LOH analysis were confirmed by direct sequencing.
Statistical analysis
The statistical difference in mutation frequencies between familial or unselected breast cancer patients and control individuals was analysed by Pearson's w 2 or Fisher's exact test. All P-values were two-sided and statistical analysis was performed with SPSS version 14.0 for Windows.
Ubiquitin binding assay GST-RAP80 fusion proteins were incubated with 500 ng of His-tagged, K63-Ub polymers (Boston Biochem, Cambridge, MA, USA) in binding buffer (20 mM Tris-Cl pH 7.5, 100 mM NaCl, 20% glycerol, 0.1% NP40, 200 mg/ml BSA, 1 mM PMSF and 30 mM imidazole) at 41C for 2h. Ni 2 þ -agarose (Qiagen, Valencia, CA, USA) was then added for 30 min at 41C, and after washes in binding buffer, proteins were eluted by incubation with binding buffer supplemented with 200 mM imidazole. Alternatively, His-tagged RAP80 protein was incubated with untagged K63-linked ubiquitin polymers using the method described above. Ubiquitin and RAP80 protein were detected by immunoblot analysis. Nitrocellulose membranes were incubated with denaturing buffer (6 M guanidine-HCl, 20 mM TrisHCl pH 7.4 and 5 mM b-mercaptoethanol) at 41C for 30 min and washed extensively with phosphate buffered saline tween-20 (PBST) before immunoblot for ubiquitin.
Antibodies
Please see Supplementary Materials for information regarding antibody identities and dilutions used.
Immunofluorescence Please see Supplementary Materials.
Laser-generated DNA DSBs DNA DSBs were generated using a PALM microBeam laser microdissection system (Carl Zeiss MicroImaging Inc, Munich, Germany) as previously described (Sobhian et al., 2007) .
Immunoprecipitation
Cells were lysed with NETN 150 (0.5% NP-40, 1 mM EDTA, 20 mM Tris-Cl pH 8, and 150 mM NaCl) for 30 min at 4 1C, followed by centrifugation. Supernatants were then incubated with Flag beads for 3 h, washed three times with NETN 150 buffer and eluted with Flag peptide for 1 h. Alternatively, cell lysates were incubated with anti-BRCA1 mouse monoclonal antibody SG11 and Protein G beads for 3 h, followed by washing and elution in Laemli buffer at 95 1C for 3 min.
Metaphase spreads
Cells were treated with 0.5 mM nocodazole for 3 h and then lysed with 75 mM KCl. Cells were fixed with a 3:1 methanol/ acetic acid solution. Metaphases were dropped onto slides kept at 65 1C, allowed to dry and stained with Geimsa. Number of sister chromatid breaks, triradials and quadriradials per metaphase were counted.
